Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 210

Sort by

Sort Order Select

Journal Articles

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

Blood (2025) 146 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2025-3031

Published: 2025

Journal Articles

Efficacy of low-dose rituximab as preemptive treatment of EBV-DNA-emia after allogeneic hematopoietic stem cell transplantation

Yi Wang, Yaoyao Shen, Ying Wang, Depei Wu

Blood (2025) 146 (Supplement 1): 2504.

https://doi.org/10.1182/blood-2025-2504

Published: 2025

Journal Articles

Clinical features and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia: A 15-year retrospective study

Yiyan Zhu, Wenzhi CAI, Xueqing Dou, Ying Wang, Xiaofei Yang, Haiping Dai, Depei Wu, Suning Chen

Blood (2025) 146 (Supplement 1): 5103.

https://doi.org/10.1182/blood-2025-5103

Published: 2025

Journal Articles

Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy

jiabiao hu, Yanan Yue, tianying chen, lina zhou, xiaomeng Bian, xiaobin song, huan chen, xu feng, yuqing lin, yixuan zhou, yingyong xu, Jianxiang Wang, Ying Wang, george church, Luhan Yang

Blood (2025) 146 (Supplement 1): 1045.

https://doi.org/10.1182/blood-2025-1045

Published: 2025

Journal Articles

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Blood (2025) 146 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2025-1042

Published: 2025

Journal Articles

First-in-human phase I study of HCB101, a 3.5th-generation CD47-SIRPα fc fusion protein: Cytopenia-sparing safety, broad pharmacologic window, and low-dose clinical activity in relapsed/refractory non-Hodgkin lymphoma

Abigail Yu, Wenyu Li, Zhili Zhou, Junjie Li, Charles Wang, Wei Ji, Ying Wang, Jian Zhang, Wei-Hong Cheng, Tian Zhang, Chihyi Hsieh, Alvin Luk, Vivien Zhang, David Sun, Yan Zhang

Blood (2025) 146 (Supplement 1): 3299.

https://doi.org/10.1182/blood-2025-3299

Published: 2025

Journal Articles

Synergistic integration of CAR-T cell pharmacokinetics and NGS-MRD evolution enables precision risk stratification in relapsed/refractory B-cell acute lymphoblastic leukemia

Runxia Gu, Shuning Wei, Shaowei Qiu, Xiaoyuan Gong, Guangji Zhang, Benfa Gong, Qiuyun Fang, Shouyun Li, Kaiqi Liu, Dong Lin, Ying Wang, Chunlin Zhou, Bingcheng LIU, Yingchang Mi, Hui Wei, Jianxiang Wang, Ying Wang

Blood (2025) 146 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2025-3366

Published: 2025

Journal Articles

Mitoxantrone liposome, subcutaneous cytarabine and G-CSF (CMG) combined with venetoclax as first-line treatment in secondary Acute Myeloid Leukemia (sAML) or elderly AML patients: A multicenter, prospective, single-arm clinical trial with concurrent control

Xiaoqian Xu, Ying Lu, Weiying Bao, Xiuhua Han, Ran An, Ying Wang, Zhiyin Liu, Jie Tian, Xingying Li, Zeying Yan, Haimin Sun, Li Chen, Sujiang Zhang

Blood (2025) 146 (Supplement 1): 3447.

https://doi.org/10.1182/blood-2025-3447

Published: 2025

Journal Articles

ZFP36L2 as a promising therapeutic target in acute graft-versus-host disease: Evidence from murine models and clinical validation

Li Li, Andie Fu, Xiwen Tong, Bin Xu, Xia Mao, Ying Wang, Shiyuan Zhang, Yi Zhu, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 5863.

https://doi.org/10.1182/blood-2025-5863

Published: 2025

Journal Articles

Real-world efficacy of inaticabtagene autoleucel in adult B-cell acute lymphoblastic leukemia patients with high-risk molecular alterations

Blood (2025) 146 (Supplement 1): 6865.

https://doi.org/10.1182/blood-2025-6865

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese adult patients with B-cell acute lymphoblastic leukemia who relapsed after their transplant: Insights from real-world data

Fen Zhou, Yuhua Li, Ying Wang, Xi Zhang, Jianmin Yang, Xiaobing Huang, JIN WANG, Xianmin Song, Xinsheng Xie, Li Wang, Jie Jin, Liye Zhong, Aibin Liang, Zhenyang Gu, Shengli Xue, Er-Lie Jiang, Baohong Ping, Heng Mei

Blood (2025) 146 (Supplement 1): 6859.

https://doi.org/10.1182/blood-2025-6859

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with Philadelphia chromosome-positive b-ALL: Insights from real-world data

Blood (2025) 146 (Supplement 1): 6855.

https://doi.org/10.1182/blood-2025-6855

Published: 2025

Journal Articles

Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFβ::MYH11(+) acute myeloid leukemia

Ziyu Feng, Jia Chen, Haiping Dai, Xiaohui Hu, Yang Xu, Shengli Xue, Huiying Qiu, Xiaowen Tang, Han Yue, Suning Chen, Depei Wu, Ying Wang

Blood (2025) 146 (Supplement 1): 1674.

https://doi.org/10.1182/blood-2025-1674

Published: 2025

Journal Articles

Impact of antibiotic exposure on CAR-T cell therapy outcomes: Analysis in multiple Myeloma and lymphoma

Bin Lv, Lingling Yin, Ying Wang, Weiying Gu, Zhenyu Li, Kailin Xu, Feng Zhu

Blood (2025) 146 (Supplement 1): 4071.

https://doi.org/10.1182/blood-2025-4071

Published: 2025

Journal Articles

Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia

Ying Wang, Qingsong Yin, Jinhai Ren, Hongsheng Zhou, Tiejun Gong, Feng Zhu, Xi Zhang, Qin Wen, Heng Mei, Wei Huang, Zhenghong Chen, Bhargava Kandala, Jingxia Chen, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 647.

https://doi.org/10.1182/blood-2025-647

Published: 2025

Journal Articles

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Yong-xian Hu, Xiaoyu Zhu, Heng Mei, Ying Wang, Yali Zhou, Kangqi Bian, Maria del Rosario, Eileen McNulty, Ming Gao, Lu Han, Wengang Ge, Jan Davidson-Moncada, Jiangtao Ren, He Huang

Blood (2025) 146 (Supplement 1): 816.

https://doi.org/10.1182/blood-2025-816

Published: 2025

Journal Articles

Engineering Quiescent Viral Entry Pathways for in Vivo CAR-T Generation via Binder-Fusogen Combinatorics

xiaoling wang, wancheng yang, kaiyuan wang, Jiapan Hu, yixuan zhou, Ying Wang, yingyong xu, Jianxiang Wang, Jeremy Luban, Luhan Yang

Blood (2025) 146 (Supplement 1): 2404.

https://doi.org/10.1182/blood-2025-2404

Published: 2025

Journal Articles

Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of zefamenib in patients with relapsed/refractory acute leukemia

Blood (2025) 146 (Supplement 1): 5209.

https://doi.org/10.1182/blood-2025-5209

Published: 2025

Journal Articles

Machine learning-based novel surfaceome classification system for acute myeloid leukemia

Heye Yu, Wenbing Liu, Qianqian Huang, Haotian Ma, Fan Ding, Yingxi Xu, Ying Wang, Qing Rao, Runxia Gu, Min Wang, Shaowei Qiu, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 452.

https://doi.org/10.1182/blood-2025-452

Published: 2025

Journal Articles

Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 study

Runxia Gu, Shaowei Qiu, Xiaoyuan Gong, Shuning Wei, Guangji Zhang, Benfa Gong, Qiuyun Fang, Shouyun Li, Kaiqi Liu, Dong Lin, Ying Wang, Chunlin Zhou, Chengcai Guo, Bingcheng LIU, Yingchang Mi, Hui Wei, Ying Wang, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 442.

https://doi.org/10.1182/blood-2025-442

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

Efficacy of low-dose rituximab as preemptive treatment of EBV-DNA-emia after allogeneic hematopoietic stem cell transplantation

Clinical features and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia: A 15-year retrospective study

Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

First-in-human phase I study of HCB101, a 3.5th-generation CD47-SIRPα fc fusion protein: Cytopenia-sparing safety, broad pharmacologic window, and low-dose clinical activity in relapsed/refractory non-Hodgkin lymphoma

Synergistic integration of CAR-T cell pharmacokinetics and NGS-MRD evolution enables precision risk stratification in relapsed/refractory B-cell acute lymphoblastic leukemia

Mitoxantrone liposome, subcutaneous cytarabine and G-CSF (CMG) combined with venetoclax as first-line treatment in secondary Acute Myeloid Leukemia (sAML) or elderly AML patients: A multicenter, prospective, single-arm clinical trial with concurrent control

ZFP36L2 as a promising therapeutic target in acute graft-versus-host disease: Evidence from murine models and clinical validation

Real-world efficacy of inaticabtagene autoleucel in adult B-cell acute lymphoblastic leukemia patients with high-risk molecular alterations

Efficacy and safety profile of inaticabtagene autoleucel in Chinese adult patients with B-cell acute lymphoblastic leukemia who relapsed after their transplant: Insights from real-world data

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with Philadelphia chromosome-positive b-ALL: Insights from real-world data

Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFβ::MYH11(+) acute myeloid leukemia

Impact of antibiotic exposure on CAR-T cell therapy outcomes: Analysis in multiple Myeloma and lymphoma

Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Engineering Quiescent Viral Entry Pathways for in Vivo CAR-T Generation via Binder-Fusogen Combinatorics

Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of zefamenib in patients with relapsed/refractory acute leukemia

Machine learning-based novel surfaceome classification system for acute myeloid leukemia

Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only